Immediate Impact

3 by Nobel laureates 4 from Science/Nature 53 standout
Sub-graph 1 of 22

Citing Papers

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
2024 Standout
Natural killer cell therapies
2024 StandoutNature
2 intermediate papers

Works of Randy A. Brown being referenced

Pemvidutide, a glp-1/glucagon dual receptor agonist, significantly reduces liver fat, fibro-inflammation, and body weight in patients with non-alcoholic fatty liver disease: a 24-week multicenter, randomized, double-blind, placebo-controlled trial
2023
Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia
2005

Author Peers

Author Last Decade Papers Cites
Randy A. Brown 520 379 319 38 1.0k
F. Maloisel 570 288 378 61 1.2k
Miki Nishimura 456 261 415 49 1.1k
Karl Gaal 324 288 259 43 1.3k
Heike Engel 677 338 209 25 1.3k
Kaori Shinjo 571 318 560 52 1.1k
Kensuke Naito 617 300 653 50 1.1k
William R. Friedenberg 358 343 227 34 1.0k
Mauricio Ocqueteau 608 210 348 32 912
A Lindemann 395 277 111 36 905
P. Koistinen 340 197 305 41 1.1k

All Works

Loading papers...

Rankless by CCL
2026